Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Individual and Synergistic Anti-Coronavirus Activities of SOCS1/3 Antagonist and Interferon α1 Peptides

Frontiers in Immunology(2022)10.3389/fimmu.2022.902956Source: DataRank Database

Individual and Synergistic Anti-Coronavirus Activities of SOCS1/3 Antagonist and Interferon α1 Peptides is a research paper published in Frontiers in Immunology (2022). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.11)OA: goldTopics (51)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Tristan R. Grams ORCID,David C. Bloom ORCID,Howard M. Johnson ORCID,Alfred S. Lewin ORCID,Chulbul M. Ahmed

Live enrichment

PubMed:35799776 PMC:PMC9254576 OpenAlex:https://openalex.org/W4283211992

NIH HHS

Grant: S10 OD026746

NIAID NIH HHS

Grant: T32 AI007110

NIH HHS

Grant: S10 OD028476

NEI NIH HHS

Grant: T32 EY007132

National Institutes of Health

Grant: 5T32AI007110-39

Basic Microbiology and Infectious Disease

National Institutes of Health

Grant: 2R01AI056152-05A2

Study of gamma interferon agonists/mimetics

FWCI

1.11

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.902956/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.902956/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.902956/full

journalhttps://doi.org/10.3389/fimmu.2022.902956

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35799776

Fields of Study

Cytokine Signaling Pathways and Interactionsinterferon and immune responsesAnimal Virus Infections Studies0301 basic medicine0303 health sciences03 medical and health sciencesAnimalsMicePeptidesSARS-CoV-2Suppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling ProteinsCOVID-19 Drug Treatment

MeSH Terms

Suppressor of Cytokine Signaling 1 ProteinSARS-CoV-2COVID-19 Drug TreatmentAnimalsPeptidesSuppressor of Cytokine Signaling ProteinsMice

Keywords

InterferonBiologyTyrosine kinasePeptideSuppressor of cytokine signaling 1CoronavirusCytokineCell cultureMolecular biologyVirologyCell biologySignal transductionChemistryBiochemistryImmunologyMedicineGeneSuppressorAntiviralsBeta-coronavirusSarscov-2Socs1/3 AntagonistSARS-CoV-2Suppressor of Cytokine Signaling ProteinsRC581-607COVID-19 Drug TreatmentMiceSuppressor of Cytokine Signaling 1 ProteinAnimalsImmunologic diseases. AllergyPeptides

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being